Regulated Bioanalytical Laboratories: Technical and Regulatory Aspects from Global Perspectives

Regulated Bioanalytical Laboratories: Technical and Regulatory Aspects from Global Perspectives

Volumn , Issue , 2010, Pages

  Zhou, Michael ^a  

^a Synta Pharmaceuticals Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84870189236     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470920671     Document Type: Book

References (494)

1. Code of Federal Regulation. Food Drug and Cosmetic Act, 21 CFR, Part 58-Good laboratory practice for nonclinical laboratory studies, 1978.
2. International Conference on Harmonization (ICH)/World Health Organization (WHO). Topic E 6 (R1) Guideline for Good Clinical Practice, 1996.
3. Code of Federal Regulation. Food Drug and Cosmetic Act 21 CFR Part 210 and 211 Current Good Manufacturing Practices, 1995-2007.
4. Organization for Economic Co-operation and Development. Principles on Good Laboratory Practice (as revised in 1997) OECD, Paris, 1998 (Series on principles of GLP and compliance monitoring, No. 1, ENV/MC/CHEM(98)17).
5. USFDA Guidance for Industry: Bioanalytical Method Validation, 2001.
6. Code of Federal Regulation. Department of Health and Human Services, Centers for Disease Control and Prevention 21 CFR, Part 493-Clinical Laboratory Improvement Act, 2004.
7. World Health Organization (WHO). Good Clinical Laboratory Practices (GCLP), 2009.
8. FDA Good Laboratory Practices (GLP) for Non-Clinical Laboratory Studies 21 CFR Part 58 Supporting Statement, 2000.
9. Code of Federal Regulation. Food Drug and Cosmetic Act, 21 CFR Part 58-Good Laboratory Practice for Nonclinical Laboratory Studies, 1978.
10. EPA Code of Federal Regulation. Federal Insecticide, Fungicide, and Rodenticide Act, 40 CFR Part 160-Good Laboratory Practice Standards.
11. Kathrin E, Preu M. Ann Ist Super Sanità 2008; 44(4):390-394.
12. International Conference on Harmonization (ICH)/World Health Organization (WHO). Topic E 6 (R1) Guideline for Good Clinical Practice, 1996.
13. International Conference on Harmonization (ICH). Harmonized Tripartite Guideline for Good Manufacturing Practices for Active Pharmaceutical Ingredients Q7, 2000.
14. Code of Federal Regulation: 21 CFR Part 11-Electronic Records and Signature Standards, 2002.
15. Mutual Acceptance of Data (MAD) Under the Organization for Economic Cooperation and Development (OECD) Council Act, 1981.
16. Ulrey AK, Curren RD, Raabe HA. AATEX 14, Special Issue. Proceedings of 6th World Congress on Alternatives and Animal Use in the Life Sciences, Tokyo, Japan; August 21-25 2007. pp. 595-600.
17. OECD Document Number 13. The Application of the OECD Principles of GLP to the Organisation and Management of Multi-Site Studies, 2002.
18. OECD Document Number 7. The Application of the GLP Principles to Short-Term Studies (Environment Monograph No. 73), 1999.
19. Food and Drug Administration. 21 CFR 320-Bioavailability and Bioequivalence Requirements (Drugs for Human Use). US Department of Health and Human Services, FDA, CDER, Rockville, MD, 2002.
20. ICH-53A. Note for Guidance on Toxicokinetics: A Guidance for Assessing Systemic Exposure in Toxicology Studies (CPMP/ICH/384/95), 1995.
21. Guidance for Industry: Bioanalytical Method Validation, US Department of Health and Human Services, FDA, CDER, CVM, May 2001.
22. ISO/IEC 17025. General requirements for the competence of testing and calibration laboratories-Accreditation by International Standardization Organization (ISO), 2005.
23. World Health Organization Special Programs for Research and Training in Tropical Diseases (TDR)-Good Clinical Laboratory Practices (GCLP), 2009.
24. Viswanathan CT, Bansal S, Booth B, et al. Quantitative bioanalyticalmethods validation and implementation: best practices for chromatographic and ligand binding assays. J AAPS 2007; 9 (Article 4): E30-E42.
25. Fox A. Inside Laboratory Management-AOAC International January/February, 2009.
26. World Health Organization Special Programs for Research&Training in Tropical Diseases (TDR)-Good Clinical Laboratory Practices (GCLP), 2009.
27. Food and Drug Administration, Bioresearch Monitoring Staff (HFC-30), Guidance for Industry, Good Laboratory Practices Questions and Answers, Rockville, MD, June 1981, revised December 1999 and September 2000; pp. 2-10.
28. FDAWarning Letter. Center for Devices and Radiological Health, Office of Compliance, Rockville, MD, April 27, 2001.
29. Food and Drug Administration. Office of Regulatory Affairs, Compliance Program Guidance Manual, Program 7348.808, Good laboratory practice (nonclinical laboratories), Appendix A, Rockville, MD, February 21, 2001.
30. Food and Drug Administration. Office of Regulatory Affairs, Compliance Policy Guide, FDA access to results of quality assurance program audits and inspections (CPG 7151.02), Rockville, MD, Revised January 3, 1996, pp. 1-2.
31. FDAWarning Letter. Reference no. CBER-00-026, Rockville, MD, July 3, 2000.
32. FDAWarning Letter. Reference no. 01HFD-45-1101, Rockville, MD, November 29, 2001.
33. FDAWarning Letter. Reference no. 01-HFD-45-0402, Rockville, MD, October 4, 2001.
34. FDAWarning Letter. Center for Veterinary Medicine, Division of Compliance, Rockville, MD, September 12, 2002.
35. FDAWarning Letter. Center for Devices and Radiological Health, Office of Compliance, Rockville, MD, July 2, 2004.
36. FDAWarning Letter. Center for Devices and Radiological Health, Office of Compliance, Rockville, MD, June 15, 2004.
37. FDAWarning Letter. Center for Devices and Radiological Health, Office of Compliance, Rockville, MD, April 16, 2004.
38. FDAWarning Letter. Center for Devices and Radiological Health, Office of Compliance, Rockville, MD, December 21, 2004.
39. Food and Drug Administration. 21 CFR part 58 Good Laboratory Practice Regulations; final rule. 52 Federal Register, September 4, 1987, pp. 33,768-33,782.
40. Shah VP, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Pharm Res 1992;9:588-592.
41. Shah VP, et al. Bioanalytical method validation-a revisit with a decade of progress. Pharm Res 2000;17(12):1551-1557.
42. Guidance for Industry-Bioanalytical Method Validation, 2001.
43. DeSilva B, Smith W, Weiner R, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res 2003;20:1885-1900.
44. Viswanathan CT, et al. Workshop/Conference Report-quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J 2007; 9 (Article 4):E30-E42.
45. Balogh MP. LCGC 22. 2004;9:890-894.
46. Balogh MP. LCGC 23. 2005;6:576-584.
47. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference Report. Eur J Drug Metab Pharmacokinet 1991;16:249-255.
48. Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services, FDA, CDER, CVM, May 2001.
49. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation-a revisit with a decade of progress. Conference Report. Pharm Res 2000;17:1551-1557.
50. FDAGuidance for Industry Part 11, Electronic Records; Electronic Signatures-Scope and Application. U.S. Department of Health and Human Services, FDA, CDER, Rockville, MD, 2003.
51. Avery G, McGee C, Falk S. Product review: implementing LIMS: a "how-to" guide. A laboratory must devote the necessary time and resources to planning, selecting, and implementing a new system. Anal Chem 2000;72 (1):57A-62A.
52. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference Report. Eur J Drug Metab Pharmacokinet 1991;16:249-255.
53. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation-a revisit with a decade of progress. Pharm Res 2000;17:1551-1557.
54. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Rockville, MD, 2001.
55. DeSilva B, Smith W, Weiner R, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res 2003;20:1885-1900.
56. Viswanathan CT, Bansal S, Booth B, et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. J AAPS 2007; 9 (Article 4): E30-E42.
57. Food and Drug Administration. Draft Guidance for Industry: Safety Testing of Drug Metabolites. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Rockville, MD, 2005.
58. International Conference on Harmonization. ICH Q2A: text on validation of analytical procedures. Fed Regist 1995; 60:FR 11260. Available at http://www.fda.gov/cder/guidance/ichq2a.pdf.
59. International Conference on, Harmonization. ICH Q2B: validation of analytical procedures: methodology. Fed Regist 1997; 62:FR 27463.Available at http://www.fda.gov/cder/guidance/1320fnl.pdf.
60. US, Department of Health and Human Services. Draft Guidance for Industry: Analytical Procedures and Methods Validation, Chemistry, Manufacturing and Controls Documentation. US Department of Health and Human Services, Food and Drug Administration, Rockville, MD, 2000.
61. United States Pharmacopoeial Convention. United States Pharmacopoeia 26, National Formulary 21, <1225> Validation of Compendial Methods. United States Pharmacopoeial Convention, Rockville, MD, 2003.
62. Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2002. Medicines Control Agency-MCA (Now Medicines and Healthcare Regulatory Agency-Medicines Section-MHRA), Her Majesty's Stationary Office, London, UK, 2002.
63. National Health andWelfare. Acceptable Methods. Drug Directorate Guidelines, National Health and Welfare, Health Protection Branch, Health and Welfare. Ottawa, Ontario, Canada, 1992.
64. Ocampo A, Lum S, Chow F. Current challenges for FDA-regulated bioanalytical laboratories for human (BA/BE) studies. Part I: Defining the appropriate compliance standards-application of the principles of FDA GLP and FDA GMP to bioanalytical laboratories. Qual Assur J 2007;11:3-15 (Wiley Inter-Science).
65. Furman WB, Layloff TP, Tetzlaff J. Validation of computerized liquid chromatographic systems. J AOAC 1994;77:1314-1318.
66. US Food and Drug Administration. General Principles of Software Validation. Final Guidance for Industry and FDAStaff. US Department of Health and Human Services, Food and Drug Administration, Rockville, MD, 2002.
67. Bansal SK, Layloff T, Bush ED, Hamilton M, Hankinson EA, Landy JS, Lowes S, Nasr MM, St. Jean PA, Shah VP. Qualification of analytical instruments for use in the pharmaceutical industry: a scientific approach. AAPS J 2004;5 (1): Article 22.
68. Food and Drug Administration. 21CFR320-Bioavailability and Bioequivalence Requirements (Drugs for Human Use). US Department of Health and Human Services, FDA, CDER, Rockville, MD, 2002.
69. Committee for Proprietary Medicinal Products. Note for Guidance on Investigation of Bioavailability and Bioequivalence. CPMP, EWP, QWP-1401/98, Canary Wharf, London, 2001.
70. Food and Drug Administration. Draft Guidance for Industry: Safety Testing of Drug Metabolites. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Rockville, MD, 2005.
71. Bakhtiar R, Ramos L, Tse FLS. Liq J Chrom Rel Technol 2002;25:507-540.
72. Zhou S, Song Q, Tang Y, Naidong W. Curr Pharm Anal 2005;1:3-14.
73. Ackermann BL, Berna MJ, Murphy AT. Curr Top Med Chem 2002;2:53-66.
74. Jemal M, Xia Y-Q. Curr Drug Metab 2006;7:491-502.
75. Naidong W. J Chromatogr B Analyt Technol Biomed Life Sci 2003;796:209-224.
76. Hsieh Y, Korfmacher WA. Curr Drug Metab 2006;7:479-489.
77. Zhang NY, Rogers K, Gajda K, Kagel JR, Rossi D. J Pharm Biomed Anal 2000;23:551-560.
78. James CA, Hill HM. AAPS J 2007;9(2): E123-E127 (Article 14).
79. Koseki N, Nakashima A, Nagae Y, Masuda N. Rapid Commun Mass Spectrom 2006;20:733-740.
80. Ma J, Shi J, Le H, Cho R, Huang JC, Miao S,Wong BK. J Chromatogr B Analyt Technol Biomed Life Sci 2008;862(1-2): 219-226.
81. Mallet CR, Lu Z, Fisk R, Mazzeo JR, Neue UD. Rapid Commun Mass Spectrom 2003;17:163-170.
82. YangAY, Sun L, Musson DG, Zhao JJ. Rapid CommunMass Spectrom 2006;20:233-240.
83. Wang PG, Wei JS, Kim G, Chang M, El-Shourbagy TA. J Chromatogr A 2006;1130:302-307.
84. Zhang J, Reimer MT, Alexander NE, Ji QC, El-Shourbagy TA. Rapid Commun Mass Spectrom 2006;20:3427-3434.
85. Ji QC, Reimer MT, El-Shourbagy TA. J Chromatogr B Analyt Technol Biomed Life Sci 2004;805:67-75.
86. Zhang N, Yang A, Rogers JD, Zhao JJ. J Pharm Biomed Anal 2004;34:175-187.
87. Xu N, Kim GE, Gregg H,Wagdy A, Swaine BA, Chang MS, El-Shourbagy TA. J Pharm Biomed Anal 2004;36:189-195.
88. Bolden RD, Hoke SH 2nd, Eichhold TH, McCauley-Myers DL, Wehmeyer KR. J Chromatogr B Analyt Technol Biomed Life Sci 2002;772:1-10.
89. Xue YJ, Akinsanya JB, Liu J, Unger SE. Rapid Commun Mass Spectrom 2006;20:2660-2668.
90. Xu XS, Yan KX, Song H, Lo MW. J Chromatogr B Analyt Technol Biomed Life Sci 2005;814:29-36.
91. Zang X, Luo R, Song N, Chen TK, Bozigian H. Rapid Commun Mass Spectrom 2005;19:3259-3268.
92. Xu RN, Fan L, Kim GE, El-Shourbagy TA. J Pharm Biomed Anal 2006;40:728-736.
93. Vintiloiu A, Mullett WM, Papp R, Lubda D, Kwong E. J Chromatogr A 2005;1082:150-157.
94. Papp R, Mullett WM, Kwong E. J Pharm Biomed Anal 2004;36:457-464.
95. Ceglarek U, Lembcke J, Fiedler GM,Werner M,Witzigmann H, Hauss JP, Thiery J. Clin Chim Acta 2004;346:181-190.
96. Ceglarek U, Casetta B, Lembcke J, Baumann S, Fiedler GM, Thiery J. Clin Chim Acta 2006;373:168-171.
97. Zhou S, Zhou H, Larson M, Miller DL, Mao D, Jiang X, NaidongW. Rapid CommunMass Spectrom 2005;19:2144-2150.
98. Chassaing C, Stafford H, Luckwell J, Wright A, Edgington A. Chromatographia 2005;62:17-24.
99. Smalley J, Kadiyala P, Xin B, Balimane P, Olah T. J Chromatogr B Analyt Technol Biomed Life Sci 2006;830:270-277.
100. Kahlich R, Gleiter CH, Laufer S, Kammerer B. Rapid Commun Mass Spectrom 2006;20:275-283.
101. Xia YQ, Liu DQ, Bakhtiar R. Chirality 2002;14:742-749.
102. Xia YQ, Bakhtiar R, Franklin RB. J Chromatogr B Analyt Technol Biomed Life Sci 2003;788:317-329.
103. Alnouti Y, Srinivasan K, Waddell D, Bi H, Kavetskaia O, Gusev AI. J Chromatogr A 2005;1080:99-106.
104. Koal T, Sibum M,Koster E, Resch K, KaeverV. Clin Chem Lab Med 2006;44:299-305.
105. Barrett YC, Akinsanya B, Chang SY, Vesterqvist O. J Chromatogr B Analyt Technol Biomed Life Sci 2005;821:159-165.
106. Bourgogne E, Grivet C, Hopfgartner G. J Chromatogr B Analyt Technol Biomed Life Sci 2005;820:103-110.
107. Calderoli S, Colombo E, Frigerio E, James CA, Sibum M. J Pharm Biomed Anal 2003;32:601-607.
108. Niederlander HA, Koster EH, Hilhorst MJ, Metting HJ, Eilders M, Ooms B, de Jong GJ. J Chromatogr B Analyt Technol Biomed Life Sci 2006;834:98-107.
109. Hu CW, Wang CJ, Chang LW, Chao MR. Clin Chem 2006;52:1381-1388.
110. Schellen A, Ooms B, van de Lagemaat, D, Vreeken R, van Dongen WD. J Chromatogr B Analyt Technol Biomed Life Sci 2003;788:251-259.
111. AlnoutiY, Li M, Kavetskaia O, Bi H, Hop CE, Gusev AI. Anal Chem 2006;78:1331-1336.
112. Kawano S, Takahashi M, Hine T, Yamamoto E, Asakawa N. Rapid Commun Mass Spectrom 2005;19:2827-2832.
113. Smalley J, Xin B, Olah TV. Rapid Commun Mass Spectrom 2009;23(21): 3457-3464.
114. Cabrera K. J Sep Sci 2004;27:843-852.
115. Li R, Dong L, Huang J. Anal Chim Acta 2005;546:167-173.
116. Wang G, Hsieh Y, Cui X, Cheng KC, Korfmacher WA. Rapid Commun Mass Spectrom 2006;20:2215-2221.
117. Borges V, Yang E, Dunn J, Henion J. J Chromatogr B Analyt Technol Biomed Life Sci 2004;804:277-287.
118. Barbarin N, Mawhinney DB, Black R, Henion J. J Chromatogr B Analyt Technol Biomed Life Sci 2003;783:73-83.
119. Huang MQ, Mao Y, Jemal M, Arnold M. Rapid Commun Mass Spectrom 2006;20:1709-1714.
120. Zeng H, Deng Y, Wu JT. J Chromatogr B Analyt Technol Biomed Life Sci 2003;788:331-337.
121. Zhou S, Zhou H, Larson M, Miller DL,Mao D, Jiang X, NaidongW. RapidCommun Mass Spectrom 2005;19:2144-2150.
122. Eerkes A, Shou WZ, Naidong W. J Pharm Biomed Anal 2003;31:917-928.
123. Xue YJ, Liu J, Unger S. J Pharm Biomed Anal 2006;41:979-988.
124. Song Q, Naidong W. J Chromatogr B Analyt Technol Biomed Life Sci 2006;830: 135-142.
125. Deng Y, Zhang H, Wu JT, Olah TV. Rapid Commun Mass Spectrom 2005;19: 2929-2934.
126. Hsieh S, Tobien T, Koch K, Dunn J., Rapid Commun Mass Spectrom 2004;18:285-292.
127. Giddings JC. Dynamics of Chromatography, Part I, Principles and Theory. Marcel Dekker, New York, 1965.
128. Al-Dirbashi OY, Aboul-Enein HY, Jacob M, Al-Qahtani K, Rashed MS. Anal Bioanal Chem 2006;385:1439-1443.
129. Wren SAC, Tchelitcheff P. J Chromatogr A 2006;1119:140-146.
130. Apollonio LG, Pianca DJ, Whittall IR, Maher WA, Kyd JM. J Chromatogr B Analyt Technol Biomed Life Sci 2006;836:111-115.
131. Shen JX, Wang H, Tadros S, Hayes RN. J Pharm Biomed Anal 2006;40:689-706.
132. Churchwell MI, Twaddle NC, Meeker LR, Doerge DR. J Chromatogr B Analyt Technol Biomed Life Sci 2005;825:134-143.
133. Yu K, Little D, Plumb R, Smith B. Rapid Commun Mass Spectrom 2006;20:544-552.
134. Ikegami T, Tanaka N. Curr Opin Chem Biol 2004;8:527-533.
135. Lindqvist A, Hilke S, Skoglund E. J Chromatogr A 2004;1058:121-126.
136. Kapron JT, Jemal M, Duncan G,Kolakowski B, Purves R. RapidCommunMass Spectrom 2005;19:1979-1983.
137. Deng Y,Wu JT, Lloyd TL, Chi CL, Olah TV, Unger SE. Rapid Commun Mass Spectrom 2002;16:1116-1123.
138. Larger PJ, Breda M, Fraier D, Hughes H, James CA. J Pharm Biomed Anal 2005;39:206-216.
139. Muller C, Schafer P, Stortzel M, Vogt S,WeinmannW. J Chromatogr B Analyt Technol Biomed Life Sci 2002;773:47-52.
140. Shen JX, Motyka RJ, Roach JP, Hayes RN. J Pharm Biomed Anal 2005;37:359-367.
141. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Anal Chem 2003;75:3019-3030.
142. Matuszewski BK. J Chromatogr B Analyt Technol Biomed Life Sci 2006;830: 293-300.
143. Little JL, Wempe MF, Buchanan CM. J Chromatogr B Analyt Technol Biomed Life Sci 2006;833:219-230.
144. Stokvis E, Rosing H, Lopez-Lazaro L, Schellens JH, Beijnen JH. Biomed Chromatogr 2004;18:400-402.
145. Jemal M, Schuster A, Whigan DB. Rapid Commun Mass Spectrom 2003;17:1723-1734.
146. Wang S, Cyronak M, Yang E. J Pharm Biomed Anal 2007;43:701-707.
147. Liang HR, Foltz RL, Meng M, Bennett P. Rapid Commun Mass Spectrom 2003;17:2815-2821.
148. Souverain S, Rudaz S, Veuthey JL. J Chromatogr A 2004;1058:61-66.
149. Constanzer ML, Chavez-Eng CM, Fu I, Woolf EJ, Matuszewski BK. J Chromatogr B Analyt Technol Biomed Life Sci 2005;816:297-308.
150. Mallet CR, Lu Z, MazzeoJr., Rapid Commun Mass Spectrom 2004;18:49-58.
151. Kitamura R, Matsuoka K, Matsushima E,KawaguchiY. J Chromatogr BBiomed Sci Appl 2001;754:113-119.
152. Lee J, Son J, Lee M, Lee KT, Kim D-H. Rapid Commun Mass Spectrom 2003;17:1157-1162.
153. Ke J, Yancey M, Zhang S, Lowes S, Henion J. J Chromatogr B 2000;742:369-380.
154. Yang L, Wu N, Clement RP, Rudewicz PJ. J Chromatogr B 2004;799:271-280.
155. Jemal M, Schuster A, Whigan DB. Rapid Commun Mass Spectrom 2003;17:1723-1734.
156. Fura A, Harper TW, Zhang H, Fung L, Shyu WC. J Pharm Biomed Anal 2003;32:513-522.
157. Tang YQ, Tollefson JA, Beato BD, Weng N. AAPS Annual Meeting, Salt Lake City, UT, October 26-30, 2003.
158. Jemal M, Xia YQ. Rapid Commun Mass Spectrom 1999;14:422-429.
159. Naidong W, Lee JW, Jiang X, Wehling M, Hulse JD, Lin P.P. J Chromatogr B 1999;735:255-269.
160. Naidong W, Jiang X, Newland K, Coe R, Lin PP, Lee JW. J Pharm Biomed Anal 2000;23:697-704.
161. Pan J, Song Q, Shi H, King M, Junga H, Zhou S, Naidong W. Rapid Commun Mass Spectrom 2004;18:2549-2557.
162. Leahy M, Felder L, Goytowski K, Shou W, Weng N. 52nd ASMS Conference on Mass Spectrometry and Allied Topics, Nashville, TN, May 23-27, 2004.
163. USDepartment of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Guidance for Industry: Bioanalytical Method Validation. May 2001.
164. Drug Importation, Act. 9 Stat 237, June 26, 1848.
165. Pure Food and Drugs, Act. 34 Stat 768, June 30, 1906.
166. Federal Food, Drug and Cosmetic (FDC), Act. United States Code (U.S.C.) Title 21, Chapter 9, June 25, 1938.
167. Kefauver-Harris Amendments, Public Law 87-781. 76 Stat 788-789, October 10, 1962.
168. Bioavailability and Bioequivalence, Requirements. 21 CFR Part 320, 2006.
169. USDepartment of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for, Veterinary. Qual Assur J 2007;11:3-15. DOI: 10.1002/qaj. Medicine. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General considerations. March 2003.
170. Good Laboratory Practice for Nonclinical Laboratory, Studies. 21 CFR Part 58, 2005.
171. Current Good Manufacturing Practice in Manufacturing, Processing, Packing or Holding of Drugs. 21 CFR Part 210, 2006.
172. Current Good Manufacturing Practice for Finished, Pharmaceuticals. 21 CFR Part 211, 2006.
173. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Scientific Investigations homepage on the Internet. Rockville, MD, updated September 21, 2006, cited September 22, 2006. About DSI, about 4 screens. Available at http://www. fda.gov/cder/Offices/DSI/aboutUs.htm.
174. LePay D. GLP, bioequivalence, and human subject protection programs. Drug Information Association. Office of Compliance, 1998. Available at http://www.fda.gov/cder/present/dia698/diafda4/diafda4 (PPT#291,6, InVivo Bioequivalence Program).
175. Food and Drug Administration. Compliance Program Guidance Manual. Bioresearch Monitoring: Human Drugs: In Vivo Bioequivalence, Chapter 48, October 1999 (CPGM 7348.001).
176. Electronic Records, Electronic, Signatures. 21 CFR Part 11, 2006.
177. USDepartment of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary, Medicine. Guidance for Industry: General Principles of Software Validation. January 2002. Qual Assur J 2007;11:3-15. DOI: (Copyright John Wiley & Sons, Ltd).
178. McDowall RD. LCGC Eur 2006;19(5): 274-282.
179. FDA Guidance for Industry on Part 11 Scope and Application, 2003.
180. FDA Current Good Manufacturing Practice for Finished Pharmaceutical Products, 21 CFR 211.
181. ICH Q7A Good Manufacturing Practice for Active Pharmaceutical Ingredients, 2000.
182. Good Automated Manufacturing Practice (GAMP) guidelines version 4, International Society of Pharmaceutical Engineering, Tampa, FL, USA, 2001.
183. GAMP Forum Good Practice Guide-Laboratory Systems; International Society for Pharmaceutical Engineering, Tampa, FL, USA, 2005.
184. United States Pharmacopeia XXIX, 2006.
185. Pharmacopoeal Forum.<1058> Analytical Equipment Qualification, January 2005.
186. McDowall D. Qual Assur J 2005;9:196-227.
187. Bansal SK, et al. Qualification of analytical instruments for use in the pharmaceutical industry: a scientific approach, American association of pharmaceutical scientists. AAPS PharmSciTech 2004;5(1): 1-8 (Article 22).
188. FDA, Innovation or Stagnation? Challenge and opportunity on the critical path to new medical products, 2004.
189. Zerhouni E. Science 2003;302:63-72.
190. DiMasi JA, Hansen RW, Grabowski HG. J Health Econ 2003;22:151-185.
191. Colburn WA. J Clin Pharmacol 1997;37:355-362.
192. Levy G. Clin Pharmacol Ther 1994;56:356-358.
193. Jadhav PR, Mehta MU, Gobburu JVS. Am Pharm Rev 2004;7:62-64.
194. Wagner JA, Williams SA, Webster CJ. Clin Pharm Ther 2007;81:104-107.
195. Pepe MS, Etzioni R, Feng Z. J Natl Cancer Inst 2001;93:1054-1061.
196. Bjornsson TD. Eur Pharm Rev 2005;1:17-21.
197. Wagner JA. Dis Markers 2002;18:41-46.
198. Lee JW, Weiner RS, Sailstad JM, Bowsher RR, Knuth DW, O'Brien PJ. Pharm Res 2005;22:499-511.
199. FDA Using Disease, Placebo, and Drug Prior Knowledge to Improve Decisions in Drug Development and at FDA, 2006.
200. Lee JW, Smith WC, Nordblom GD, Bowsher RR. Validation of assays for the bioanalysis of novel biomarkers. In: Bloom JC, Dean RA,editors. Biomarkers in Clinical Drug Development, Marcel Dekker, New York, 2003, pp. 119-149.
201. Lee JW, Devanarayan V, Barrett YC, Allinson J, Fountain S, Keller S, Weinryb I, Green M, Duan L, Rogers JA, Millham R, O'Brien PJ, Sailstad J, Khan M, Weiner RS, Ray C, Wagner JA. Pharm Res 2006;23:312-328.
202. Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, Pickeral O, Low J, Steinberg SM, Gutierrez M. Nat Rev Cancer 2007;7:131-139.
203. Stoch SA, Wagner JA. Int J Pharm Med 2007;21:271-277.
204. Roessler M, Rollinger W, Mantovani-Endl L, Hagmann ML, Palme S, Berndt P, Engel AM, Pfeffer M, Karl J, Bodenmuller H, Ruschoff J, Henkel T, Rohr G, Rossol S, Rosch W, Langen H, Zolg W, Tacke M. Mol Cell Proteomics 2006;5: 2092-2101.
205. Manne U, Srivastava RG, Srivastava S. Drug Discov Today 2005;10:965-980.
206. Pan S, Shi M, Jin J, Albin RL, Lieberman A, Gearing M, Lin B, Pan C, Yan X, Kashima DT, Zhang J. Mol Cell Proteomics 2007;6(10): 1818-1823.
207. RikovaK, Guo A, Zeng Q, Possemato A,Yu J, Haack H, Nardone J, Lee K, ReevesC, LiY, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb MJ. Cell 2007;131:1190-1203.
208. Han WK, Bonventre JV. Curr Opin Crit Care 2004;10:476-482.
209. McIntosh MW, Liu Y, Drescher C, Urban N, Diamandis EP. Clin Cancer Res 2007;13:4422-4428.
210. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G,Wetzel R,WangY, MacNeill J, Mitchell J, Gygi SP, Rush J, Polakiewicz RD, Comb MJ. Proc Natl Acad Sci USA 2008;105:692-697.
211. Lambert JP, Ethier M, Smith JC, Figeys D. Anal Chem 2005;15:3771-3788.
212. Washburn MP, Wolters D, YatesJr., Nat Biotechnol 2001;19:242-247.
213. Kirkpatrick DS, Gerber SA, Gygi SP. Methods 2005;35:265-273.
214. Everley PA, Bakalarski CE, Elias JE, Waghorne CG, Beausoleil SA, Gerber SA, Faherty BK, Zetter BR, Gygi SP. J Proteome Res 2006;5:1224-1231.
215. Everley PA, Krijgsveld J, Zetter BR, Gygi SP. Mol Cell Proteomics 2004;3:729-735.
216. Bakalarski CE, Haas W, Dephoure NE, Gygi SP. Anal Bioanal Chem 2007;389: 1409-1419.
217. Turck CW, Falick AM, Kowalak JA, Lane WS, Lilley KS, Phinney BS, Weintraub ST, Witkowska HE, Yates NA. Mol Cell Proteomics 2007;6:1291-1298.
218. Wehr T. LC-GC, 2007;25:1.
219. Veenstra TD. J Chromatogr B 2007;847:3-11.
220. Sahab ZJ, Semaan SM, Sang QA. Biomark Insights 2007;2:21-43.
221. Lee JW, Hall M. J Chromatogr B 2009;877:1259-1271.
222. Anderson L, Hunter CL. Mol Cell Proteomics 2006;5:573-588.
223. Everley PA, Gartner CA, HaasW, Saghatelian A, Elias JE, Cravatt BF, Zetter BR, Gygi SP. Mol Cell Proteomics 2007;6:1771-1777.
224. Niederkofler EE, Tubbs KA, Gruber K, Nedelkov D, Kiernan UA, Williams P, Nelson RW. Anal Chem 2001;73:3294-3299.
225. Lee JW,and Hall M. J Chromatogr B 2009;877:1259-1271.
226. Stephen RM, Gillies RJ. Pharm Res 2007;24:1172-1185.
227. Leong FJ, Leong AS. J Postgrad Med 2004;50:62-69.
228. Mitsui K, Doi H, Nukina N. Methods Enzymol 2006;412:63-76.
229. Ghattas H, Darboe BM,Wallace DL, Griffin GE, Prentice AM, Macallan DC. Trans R Soc Trop Med Hyg 2005;99:675-685.
230. Lee MS, Kerns E.H. Mass Spectrom Rev 1999;183-4:187-279.
231. James CA, Breda M, Frigerio E. J Pharm Biomed Anal 2004;35(4):887-893.
232. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A. et al. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetics studies J Pharm Sci 1992;81:309-312.
233. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ. et al. Bioanalytical method validation: a revisit with a decade of progress. Pharm Res 2000;17:1551-1557.
234. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Guidance for Industry: Bioanalytical Method Validation, May 2001.
235. Food and Drug Administration Bioresearch monitoring: human drugs: in vivo bioequivalence. Compliance Program Guidance Manual (CPGM 7348.001), Chapter 48, October 1999.Available at http://www.fda.gov/ora/compliance_ref/bimo/7348_001/foi48001.pdf.
236. Food and Drug Administration. Bioavailability and Bioequivalence Requirements, 21CFR Part 820, 2005.
237. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine, (2001). Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations, March 2003.
238. Food and Drug Administration. Good Laboratory Practice for Nonclinical Laboratory Studies, 21 CFR Part 58, 2005.
239. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Scientific Investigations homepage on the Internet. Rockville, MD updated 21 September 21, 2006; cited September 22, 2006. About DSI; about 4 screens. Available at http://www. fda.gov/cder/Offices/DSI/aboutUs.htm.
240. LePay D. GLP, bioequivalence, and human subject protection programs. In Drug Information Association, Office of Compliance, 1998. Available at http://www.fda.gov/cder/present/dia698/diafda4/dia fda4.PPT.
241. Miller KJ, Bowsher RR, Celniker A, Gibbons J, Gupta S, Lee JW. et al. Workshop on bioanalytical methods validation for macromolecules: summary report. Pharm Res 2001;189:1373-1383.
242. Timm U, Wall M, Dell D. J Pharm Sci 1985;749:972-977.
243. Kringle R, Hoffman D, Newton J, Burton R. Drug Info J 2001;35:1261-1270.
244. Weng N, Halls TDJ. Systematic troubleshooting for LC-MS/MS. Pharm Technol 2002;151:22-26, 49.
245. King R, Bonfiglio R, Fernandez-Metler C, Miller-Stein C, Olah T. J Am Soc Mass Spectrom 2000;11:942-950.
246. Karns H.T. Am Pharm Rev 2003;61:106-107.
247. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25.
248. Khan S, Teitz DS, Jemal M. Anal Chem 1998;70:1622-1628.
249. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Ther Drug Monit 2003;25:1-16.
250. Jemal M, Ouyang Z, Chen BH, Teitz D. Rapid Commun Mass Spectrom 1999;13:1003-1015.
251. Jemal M, Rao S, Salahudeen I, Chen BH, Kates R. J Chromatogr B 1999;736:19-41.
252. Ong VS, Stamm GE, Menacherry ES, Chu S-Y. J Chromatogr B 1998;710:173-182.
253. Fura A, Harper TW, Zhang H, Fung L, Shyu WC. J Pharm Biomed Anal 2003;32:513-522.
254. Boink ABTJ, BuckleyBM, Christiansen TF, Covington AK, Maas AHJ,Muller-Plathe O, Sachs C, Siggaard-Anderson O. Clin Chim Acta 1991;202:S13-S22.
255. Xia Y-Q, Whigan DB, Jemal M. Rapid Commun Mass Spectrom 1999;13:1611-1621.
256. Wang CJ, Pao LH, Hsiong CH, Wu CY, Whang-Peng JJK, Hu OYP. J Chromatogr B 2003;796:283-291.
257. Testa B, Carrupt PA, Gal J. Chirality 1993;5:105-111.
258. Won CM. Pharm Res 1994;11:165-170.
259. Gilbert HF. Meth Enzymol 1995;251:8-29.
260. Evans MJ, Livesey JH, Ellis MJ, Yandle TG. Clin Biochem 2001;34:107-112.
261. Testa B, Mayer JM. Hydrolysis in Drug and Prodrug Metabolism. Wiley-VCH Verlag GmbH, Zurich, 2003.
262. Jemal M, Khan S, Teitz DS, McCafferty JA, Hawthorne DJ. Anal Chem 2001;73:5450-5456.
263. Redinbo MR, Potter PM. Drug Discov Today 2005;10:313-325.
264. Satoh T, Taylor P, BosronWF, Sanghani SP, Hosokawa M, La Du BN. Drug Metab Dispos 2002;30:488-493.
265. Watt AP, Morrison D, Locker KL, Evans DC. Anal Chem 2000;72:979-984.
266. Berna M, Murphy AT, Wilken B, Ackermann B. Anal Chem 2002;74:1197-1201.
267. Sadagopan NP, Li W, Cook JA, Galvan B, Weller DL, Fountain ST, Cohen LH. Rapid Commun Mass Spectrom 2003;17:1065-1070.
268. Teitz DS, Khan S, Powell ML, Jemal M. J Biochem Biophys Methods 2000;45: 193-204.
269. Heath TG, McLaughlin K, Knotts K. Precipitation of plasma proteins with a trichloroacetic acid solution for direct quantitative analysis by LC-MS/MS. The 46th ASMS Conference on Mass Spectrometry and Allied Topics, Orlando, FL, USA, 1998, p. 1400.
270. Blanchard J. Evaluation of the relative efficacy of various techniques for deproteinizing plasma samples prior to HPLC analysis. J Chromatogr B 1981;226:455-460.
271. Kaye B, Herron WJ, Macrae PV, Robinson S, StopherDA,Venn RF,WildW. Rapid, solid phase extraction technique for the high-throughput assay of darifenacin in human plasma. Anal Chem 1996;68:1658-1660.
272. Janiszewski JS, Schneider RP, Hoffmaster K, Swyden M,Wells D, Fouda H. Automated sample preparation using membrane microtiter extraction for bioanalytical mass spectrometry. Rapid Commun Mass Spectrom 1997;11:1033-1037.
273. Steinborner S, Henion J. Liquid-liquid extraction in the 96-well plate format with SRM LC/MS quantitative determination of methotrexate and its major metabolite in human plasma. Anal Chem 1999;71:2340-2345.
274. Zweigenbaum J, Heinig K, Steinborner S, Wachs T, Henion J. High-throughput bioanalytical LC-MS/MS determination of benzodiazepines in human urine: 1000 samples per 12 hours. Anal Chem 1999;71:2294-2300.
275. Hendriks G, Uges DR, Franke JP. J Chromatogr B 2007;853 (1-2): 234-241.
276. Needham SR, Cole MJ, Fouda HG. Direct plasma injection for HPLC/MS quantitation of the anxiolytic agent CP-93,393. J Chromatogr B 1998;718:87-94.
277. Jemal M, Qing Y, Whigan DB. The use of high-flow HPLC coupled with positive and negative ion electrospray tandem mass spectrometry for quantitative bioanalysis via direct injection of the plasma/serum samples. Rapid Commun Mass Spectrom 1998;12:1389-1399.
278. Ayrton J, Dear GJ, Leavens WJ, Mallett DN, Plumb RS. Optimization and routine use of generic ultra-high flow rate HPLC with mass spectrometric detection for the direct online analysis of pharmaceuticals in plasma. J Chromatogr A 1998;828:199-207.
279. Jemal M, Teitz D, Ouyang Z, Khan S. J Chromatogr B 1999;732:501.
280. Wells DA. High Throughput Bioanalytical Sample Preparation: Methods and Automation Strategies. Elsevier, Amsterdam, 2003.
281. Ouyang Z, Khan S, Jemal M. Proceedings of the 53rd ASMS Conference on Mass Spectrometry and Allied Topics, San Antonio, Texas, USA, 2005.
282. Mallet CR, Lu Z, Fisk R, Mazzeo JR, Neue UD. Rapid Commun Mass Spectrom 2003;17:163-170.
283. AbuRuz S, Millership J, McElnay J. J Chromatogr B 2003;798:203-209.
284. Wachs T, Henion J. Anal Chem 2003;75:1769-1775.
285. Zhao JJ, Xie IH, Yang AY, Roadcap BA, Rogers JD. J Mass Spectrom 2000;35:1133-1143.
286. Bolden RD, HokeII, SH, Eichhold TH, McCauley-Myers DL, Wehmeyer KR. J Chromatogr B 2002;772:1-10.
287. Eerkes A, Shou WZ, Naidong W. J Pharm Biomed Anal 2003;31:917-928.
288. Xu N, Kim GE, Gregg H,Wagdy A, Swaine BA, Chang MS, El-Shourbagy TA. J Pharm Biomed Anal 2004;36:189-195.
289. Ji QC, Reimer MT, El-Shourbagy TA. J Chromatogr B 2004;805:67-75.
290. Xue Y-J, Pursley J, Arnold ME. J Pharm Biomed Anal 2004;34:369-378.
291. Zhang N, Yang A, Rogers JD, Zhao JJ. J Pharm Biomed Anal 2004;34:175-187.
292. O'Connor D, Clarke DE, Morrison D, Watt AP. Rapid Commun Mass Spectrom 2002;16:1065-1071.
293. Polson C, Sarkar P, Incledon B, Raguvaran V, Grant R. J Chromatogr B 2003;785:263-275.
294. Ayrton J, Dear GJ, Leavens WJ, Mallett DN, Plumb RS. Rapid Commun Mass Spectrom 1997;11:1953-1958.
295. Ayrton J, Dear GJ, Leavens WJ, Mallett DN, Plumb RS. J Chromatogr A 1998;828:199-207.
296. Souverain S, Rudaz S, Veuthey J-L. J Chromatogr B 2004;801:141-156.
297. Jemal M, Xia Y-Q, Whigan DB. Rapid Commun Mass Spectrom 1998;12:1389-1399.
298. Jemal M, Ouyang Z, Xia Y-Q, Powell ML. Rapid Commun Mass Spectrom 1999;13:1462-1477.
299. Xia Y-Q, Hop CECA, Liu DQ, Vincent SH, Chiu S-HL. Rapid Commun Mass Spectrom 2001;15:2135-2144.
300. Herman JL. Rapid Commun Mass Spectrom 2002;16:421-426.
301. Herman JL. Rapid Commun Mass Spectrom 2005;19:696-700.
302. Chiap P, Rbeida O, Christiaens B, Hubert Ph, Lubda D, Boos K-S, Crommen J. J Chromatogr A 2002;975:145-155.
303. Papp R, Mullett WM, Kwong E. J Pharm Biomed Anal 2004;36:457-464.
304. Hsieh Y, Brisson J-M, Ng K, KorfmacherWA. J Pharm Biomed Anal 2002;27:285-293.
305. Xia Y-Q, Liu DQ, Bakhtiar R. Chirality 2002;14:742-749.
306. Xia Y-Q, Bakhtiar R, Franklin RB. J Chromatogr B 2003;788:317-329.
307. Wu ST, Xing J, Apedo A, Wang-Iverson DB, Olah TV, Tymiak AA, Zhao N. Rapid Commun Mass Spectrom 2004;18:2531-2536.
308. Cassiano NM, Barreriro JC, Moraes MC, Cliverira RY, Cass QB. Bioanalysis 2009;1 (3): 577-594.
309. Plumb R, Dear G, Mallett D,Ayrton J. Rapid Commun Mass Spectrom 2001;15:986-993.
310. Hsieh Y, Wang G, Wang Y, Chackalamannil S, Korfmacher WA. Anal Chem 2003;75:1812-1818.
311. Zeng H, Deng Y, Wu J-T. J Chromatogr B 2003;788:331-337.
312. Gilbert JD, Olah TV, McLoughlin DA. HPLC with atmospheric pressure ionization tandem mass spectrometry as a tool in quantitative bioanalytical chemistry. In: Snyder AP, editor. Biological and Biotechnological Applications of Electrospray Ionization MS, The American Chemical Society, New York, 1996, pp. 330-350.
313. Bruins AP. Atmospheric pressure ionization mass spectrometry I. Instrumentation and ionization techniques. Trends Anal Chem 1994;13:37-43.
314. Bruins AP. Atmospheric pressure ionization mass spectrometry II. Applications in pharmacy, biochemistry and general chemistry. Trends Anal Chem 1994;13:81-90.
315. Covey T. Analytical characteristics of the electrospray ionization process. In: Snyder AP, editor. Biochemical and Biotechnological Applications of Electrospray Ionization MS. The American, Chemical Society, Washington, DC, 1996, pp. 21-59.
316. Hiller DL, Zuzel TJ, Williams JA, Cole RO. Rapid scanning technique for the determination of optimal tandem MS conditions for quantitative analysis. Rapid Commun Mass Spectrom 1997;11:593-597.
317. Wang T, Zeng L, Strader T, Burton L, Kassel DB. Anewultra-high throughput method for characterizing combinatorial libraries incorporating a multiple probe autosampler coupled with flow injection mass spectrometry analysis. Rapid Commun Mass Spectrom 1998;12:1123-1129.
318. Jemal M, Ouyang Z. Rapid Commun Mass Spectrom 2003;17:24-38.
319. Xu X, Veals J, Korfmacher WA. Rapid Commun Mass Spectrom 2003;17:832-837.
320. Hughes N, Winnik W, Dunyach J-J, Amad M, Splendore M, Paul G. J Mass Spectrom 2003;38:743-751.
321. Yang L, Amad MA,WinnikWM,Schoen AE, Schweingruber H, Mylchreest I, Rudewicz PJ. Rapid Commun Mass Spectrom 2002;16:2060-2066.
322. Raffaelli A, Saba A. Mass Spectrom Rev 2003;22:318-331.
323. Kauppila TS, Kuuranne T, Meurer EC, Eberlin MN, Kotiaho T, Kostiainen R. Anal Chem 2002;74:5470-5479.
324. Hanold KA, Fisher SM, Cormia PH, Miller CE, Syage JA. Anal Chem 2004;76:2842-2851.
325. Wang G, Hsieh Y, Korfmacher WA. Anal Chem 2005;77:541-548.
326. Hsieh Y, Merkle K, Wang G, Brisson J-M, And Korfmacher WA. Anal Chem 2003;75:3122-3127.
327. Guevremont R. J Chromatogr A 2004;1058:3-19.
328. Kapron JT, Jemal M, Duncan G, Kolakowski B, Purves R. Rapid Commun Mass Spectrom 2005;19:1979-1983.
329. Shvartsburg AA, Tang K, Smith RD. J Am Soc Mass Spectrom 2005;16:2-12.
330. Venne K, Bonneil E, Eng K, Thibault P. Anal Chem 2005;77:2176-2186.
331. Kolakowski BM, Mester Z. Analyst 2007;132 (9): 842-864.
332. Hatsis P, Kapron JT. Rapid Commun Mass Spectrom 2008;22 (5): 735-738.
333. O'Donnell RM, Sun XB, Harrington P. Trac-Trends Anal Chem 2008;27 (1): 44-53.
334. Singh G, Gutierrez A, Xu K, Blair IA. Anal Chem 2000;72:3007-3013.
335. Hayen H, Jachmann N, Vogel M, Karst U. Analyst 2002;127:1027-1030.
336. Higashi T, Takido N, Yamauchi A, Shimada K. Anal Sci 2002;18:1301-1307.
337. Jemal M, Almond R, Ouyang Z, Teitz D. J Chromatogr B 1997;703:167-175.
338. Wu Z, Gao W, Phelps MA, Wu D, Miller DD, Dalton JT. Anal Chem 2004;76: 839-847.
339. Jemal M, Hawthorne DJ. Rapid Commun Mass Spectrom 1999;13:61-66.
340. Cai Y, Cole RB. Anal Chem 2002;74:985-991.
341. Vai Y, Concha MC, Murray JS, Cole RB. J Am Soc Mass Spectrom 2002;13:1360-1369.
342. Kumar MR, Prabhakar S, Kumar MK, Reddy TJ, Vairamani M. Rapid Commun Mass Spectrom 2004;18:1109-1115.
343. Sheen JF, Her GR. Rapid Commun Mass Spectrom 2004;18:1911-1918.
344. Harvey DJ. J Am Soc Mass Spectrom 2005;16:622-630.
345. Zhao JJ, Yang AY, Rogers JD. J Mass Spectrom 2002;37:421-433.
346. Miao X-S, Metcalfe CD. J Chromatogr A 2003;998:133-141.
347. Teshima K, Kondo T, Maeda C, Oda T, Hagimoto T, Tsukuda R, Yoshimura Y. J Mass Spectrom 2002;37:631-638.
348. Miao X-S, Metcalfe CD. J Chromatogr A 2003;998:133-141.
349. Mortier JA, Zhang G-F, Peteghem CHV, Lambert WE. J Am Soc Mass Spectrom 2004;15:585-592.
350. Dams R, Benijts T,GuntherW, LambertW, De Leenheer Rapid Commun Mass Spectrom 2002;16:1072-1077.
351. Anari R, Bakhtiar R, Zhu B, Huskey S, Franklin RB, Evans DC. Anal Chem 2002;74:4136-4144.
352. Zhang F, Bartels MJ, Brodeur JC, McClymont EL,Woodburn KB. Rapid Commun Mass Spectrom 2004;18:2739-2742.
353. Xia Y-Q, Chang SW, Patel S, Bakhtiar R, Karanam B, Evans DC. Rapid Commun Mass Spectrom 2004;18:1621-1628.
354. Nelson RE, Grebe SK, Okane DJ, Singh RJ. Clin Chem 2004;50:373-384.
355. Shou WZ, Jiang X, Naidong W. Biomed Chromatogr 2004;18:414-421.
356. Barry SJ, Carr RM, Lane SJ, Leavens WJ, Manning CO, Monté S, Waterhouse I. Rapid Commun Mass Spectrom 2003;17:484-497.
357. Zuo M, Gao M-J, Liu Z, Cai L, Duan G-L. J Chromatogr B 2005;814:331-337.
358. van Leeuwen SM, Hendriksen L, Karst U. J Chromatogr A 2004;1058:107-112.
359. Cartwright AJ, Jones P, Wolff J-C, Evans EH. Rapid Commun Mass Spectrom 2005;19:1058-1062.
360. Minkler PE, Ingalls ST, Hoppel CL. Anal Chem 2005;77:1448-1457.
361. Liu Z, Minkler PE, Lin D, Sayre LM. Rapid Commun Mass Spectrom 2004;18:1059-1065.
362. Song Y, Quan Z, Evans JL, Byrd EA, Liu Y-M. Rapid Commun Mass Spectrom 2004;18:989-994.
363. Marand , Karlsson D, Dalene M, Skarping G. Analyst 2004;129:522-528.
364. Nordstrom A, Tarkowski P, Tarkowska D, Dolezal K, stot C, Sandberg G, Moritz T. Anal Chem 2004;76:2869-2877.
365. Julka S, Regnier FE. Anal Chem 2004;76:5799-5806.
366. Yang E, Wang S, Bowen C, Kratz J, Cyronak MJ, Dunbar JR. Rapid Commun Mass Spectrom 2005;19:759-766.
367. Higashi T, Shimada K. Anal Bioanal Chem 2004;378:875-882.
368. Korfmacher WA, Veals J, Dunn-Meynell K, Zhang X, Tucker G, Cox KA, Lin C. Demonstration of the capabilities of a parallel LC-MS/MS system for use in the analysis of drug discovery plasma samples. Rapid Commun Mass Spectrom 1999;13:1991-1998.
369. Kostianen R, Bruins AP. Effect of multiple sprayers on dynamic range and flow rate limitations in electrospray and ionspray MS. Rapid Commun Mass Spectrom 1994;8:549-558.
370. Shia J, Wang C. Applications of multiple channel electrospray ionization sources for biological sample analysis. J Mass Spectrom 1997;32:247-250.
371. Andrien BA, Whitehouse C, Sansone MA. Multiple inlet probes for electrospray and APCI sources. The 46th ASMS Conference on Mass Spectrometry and Allied Topics, Orlando, FL, USA, 1998, p. 889.
372. de Biasi V, Haskins N, Organ A, Bateman R, Giles K, Jarvis S. High throughput liquid/mass spectrometric analysis using a novel multiplexed electrospray interface. Rapid Commun Mass Spectrom 1999;13:1165-1168.
373. Plumb R, Castro-Perez J, Granger J, Beattie I, Joncour K, Wright A. Rapid Commun Mass Spectrom 2004;18:2331-2337.
374. Neue UD. HPLC Columns: Theory Technology and Practice. Wiley-VCHVerlag GmbH, New York, 1997.
375. Tettey-Amlalo RN, Kanfer I. J Pharm Biomed Anal 2009;50 (4): 580-586.
376. Wehr T. LCGC North Am 2002;20 (1): 41-47.
377. Przybyciel M, Majors RE. LCGC North Am 2002;20 (6): 516-523.
378. Guo Y, Gaiki S. J Chromatogr A 2005;1074:71-80.
379. Grumbach ES,Wagrowski-Diehl DM, Mazzeo JR, Alden B, Iraneta PC. LCGCNorthAm 2004;22 (10): 1010-1023.
380. Li AC, Junga H, Shou WZ, Bryant MS, Jiang X-Y, Naidong W. Rapid Commun Mass Spectrom 2004;18:2343-2350.
381. Pan J, Song Q, Shi H, King M, Junga H, Zhou S, Naidong W. Rapid Commun Mass Spectrom 2004;18:2549-2557.
382. Brown SD, White CA, Bartlett MG. Rapid Commun Mass Spectrom 2002;16:1871-1876.
383. Oertel R, Neumeister V, Kirch W. J Chromatogr A 2004;1058:197-201.
384. Majors RE, Przybyciel M. LCGC North Am 2002;20 (7): 584-593.
385. Layne J. J Chromatogr A 2002;957:149-164.
386. Walter TH, Iraneta P, Capparella M. J Chromatogr A 2005;1075:177-183.
387. Xing J, Apedo A, Tymiak A, Zhao N. Rapid Commun Mass Spectrom 2004;18: 1599-1606.
388. Apffel A, Fischer S, Goldberg G, Goodley PC, Kuhlmann FE. J Chromatogr A 1995;712: 177-190.
389. Fuh M-R, Huang C-H, Wu T-U, Lin S-L, Pan WHT. Rapid Commun Mass Spectrom 2004;18:1711-1714.
390. Gustavsson SA, Samskog J, Markides KE, Långstrom B. J Chromatogr A 2001;937: 41-47.
391. PetritisK, Brussaux S,Guenu S, Elfakir C, Dreux M. J Chromatogr A 2002;957:173-185.
392. McCalley DV. J Chromatogr A 2004;1038:77-84.
393. Wu T-U, Fuh M-R. Rapid Commun Mass Spectrom 2005;19:775-780.
394. Tuytten R, Lemière F, Dongen WV, Esmans EL, Slegers H. Rapid Commun Mass Spectrom 2002;16:1205-1215.
395. Pruvost A, Becher F, Bardouille P, Guerrero C, Creminon C, Dekfraissy JF, Goujard C, Grassi J, Benech H. Rapid Commun Mass Spectrom 2001;15:1401-1408.
396. Jemal M, Xia Y-Q. Rapid Commun Mass Spectrom 1999;13:97-106.
397. Weng Naidong, Lee JW, Jiang X, Wehling M, Hulse JD, Lin PP. J Chromatogr B 1999;735:255-269.
398. Jemal M, Huang M, Mao Y, Whigan D, Schuster A. Rapid Commun Mass Spectrom 2000;14:1023-1028.
399. Jemal M, Ouyang Z, Powell M. J Pharm Biomed Anal 2000;23:323-340.
400. Weng, Naidong W, Jiang X, Newland K, Coe R, Lin P, Lee J. J Pharm Biomed Anal 2000;23:697-704.
401. Liu DQ, Pereira T. Rapid Commun Mass Spectrom 2002;16:142-146.
402. Ayrton J, Clare RA, Dear GJ, Mallett DN, Plumb RS. Rapid Commun Mass Spectrom 1999;13:1657-1662.
403. Yan Z, Caldwell GW, Jones WJ, Masucci JA. Rapid Commun Mass Spectrom 2003;17:1433-1442.
404. Jemal M, Ouyang Z. Rapid Commun Mass Spectrom 2000;14:1757-1765.
405. Jemal M, Xia Y-Q. J Pharm Biomed Anal 2000;22:813-827.
406. Kebarle P, Tang L. Anal Chem 1993;65:972A-986A.
407. Enke CG. Anal Chem 1997;69:4885-4893.
408. Pan P, McLuckey SA. Anal Chem 2003;75:5468-5474.
409. King R, Bonfiglio R, Fernandez-Metzler C, Miller-Stein C, Olah T. J Am Soc Mass Spectrom 2000;11:942-950.
410. Bonfiglio R, King RC, Olah TV, Merkle K. Rapid Commun Mass Spectrom 1999;13:1175-1185.
411. Kaufmann A, Butcher P. Rapid Commun Mass Spectrom 2005;19:611-617.
412. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Anal Chem 2003;75:3019-3030.
413. AhnoffM,Wurzer A, Lindmark B, Jussila R. Proceedings of the 51st ASMS Conference on Mass Spectrometry and Allied Topics, Montreal, Canada, 2003.
414. Bennett PK, Meng M, Van Horne KC. Proceedings of the 53rd ASMS Conference on Mass Spectrometry and Allied Topics, San Antonio, Texas, USA, 2005.
415. Shen JX, Motyka RJ, Roach JP, Hayes RN. J Pharm Biomed Anal 2005;37:359-367.
416. Tong XS, Wang J, Zheng S, Pivnichny JV, Grifin PR, Shen X, Donnelly M, Vakerich K, Nunes C, Fenyk-Melody J. Anal Chem 2002;74:6305-6313.
417. Shou WZ, Naidong W. Rapid Commun Mass Spectrom 2003;17:589-597.
418. Mei H, Hsieh Y, Nardo C, Xu X,Wang S, Ng K, KorfmacherWA. Rapid Commun Mass Spectrom 2003;17:97-103.
419. Xia Y-Q, Patel S, Bakhtiar R, Franklin RB, Doss GA. J Am Soc Mass Spectrom 2005;16:417-421.
420. Liang HR, Foltz RL, Meng M, Bennett P. Rapid Commun Mass Spectrom 2003;17:2815-2821.
421. Sojo LE, Lum G, Chee P. Analyst 2003;128:51-54.
422. Cech NB, Enke CG. Anal Chem 2001;73:4632-4639.
423. Schmidt A, Karas M, Dulcks T. J Am Soc Mass Spectrom 2003;14:492-500.
424. Sancho JV, Pozo OJ, et al. Rapid Commun Mass Spectrom 2002;16:639-645.
425. Liang HR, Foltz RL, et al. Rapid Commun Mass Spectrom 2003;17:2815-2821.
426. Gangl ET, Annan M, et al. Anal Chem 2001;73:5635-5644.
427. Zrostlikova J, Hajslova J, et al. J Chromatogr A 2002;973:13-26.
428. Choi BK, Gusev AI, Hercules DM. Anal Chem 1999;71:4107-4110.
429. Ito S, Tsukada K. J Chromatogr A 2002;943:39-46.
430. Choi BK, Hercules DM, Gusev AI Fres. J Anal Chem 2001;369:370-377.
431. Benijts T, Dams R, et al. J Chromatogr A 2004;1029:153-159.
432. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Anal Chem 1998;70:882-889.
433. Ayrton J, Dear GJ, Leavens WJ, Mallett DN, Plumb RS. J Chromatogr B 1998;709:243-254.
434. Cole RO, Laws KA, Hiller DL, Kiplinger JP, Ware RS. Am Lab 1998;30:15-20.
435. Jemal M, Xia Y. Rapid Commun Mass Spectrom 1999;13:97-106.
436. Voyksner RD. Combining liquid chromatography with electrospray MS. In: Cole R, editor. Electrospray Ionization Mass Spectrometry: Fundamentals, Instrumentation and Applications, Wiley, New York, 1996, pp. 323-341.
437. Axelsson BO, Jornten-Karlsson M, Michelsen P, Abou-Shakra F. Rapid Commun Mass Spectrom 2001;15:375-385.
438. Nicholson JK, Lindon JC, Scarfe G,Wilson ID, Abou-Shakra F, Castro-Perez J, Eaton A, Preece S. Analyst 2000;125:235-236.
439. Nicholson JK, Lindon JC, Scarfe GB,Wilson ID, Abou-Shakra F, Sage AB, Castro-Perez J. Anal Chem 2001;73:1491-1494.
440. NIH. Clin Pharmacol Ther 2001;69:89-95.
441. Sarker D, Workman P. Adv Cancer Res 2007;96:213-268.
442. Lee JW, Devanarayan V, Barrett YC,Weiner R, Allinson J, Fountain S,Keller S,Weinryb I, Green M, Duan L, Rogers JA, Millham R, O'Brien PJ, Sailstad J, Khan M, Ray C, Wagner JA. Pharm Res 2006;23:312-328.
443. Szekely-Klepser G,Wade K,Woolson D, Brown R, Fountain S, Kindt E. J Chromatogr B 2005;826:31-40.
444. Kindt E, Shum Y, Badura L, Snyder PJ, Brant A, Fountain S, Szekely-Klepser G. Anal Chem 2004;76:4901-4908.
445. van der Merwe DE, Oikonomopoulou K, Marshall J, Diamandis EP. Adv Cancer Res 2007;96:23-33.
446. Lee JW, Weiner RS, Sailstad JM, Bowsher RR, Knuth DW, O'Brien PJ, Fourcroy JL, Dixit R, Pandite L, Pietrusko RG, Soares HD, Quarmby V, Vesterqvist OL, Potter DM, Witliff JL, Fritche HA, O'Leary T, Perlee L, Kadam S, Wagner JA. Pharm Res 2005;22:499-511.
447. Mats Bergstro, Anders Grahne, Bengt Langstrom. Eur J Clin Pharmacol 2003;59:357-366.
448. Spooner N, Barfield M, Lad R, Parry S, Fowles S. J Chromatogr B 2008;870:32-37.
449. Li W, Tse FLS. Biomed Chromatogr 2010;24:49-65.
450. Iwatsubo T, Ito K, Kanamitsu S, Nakajima Y, Sugiyama Y. Ann Rev Pharmacol Toxicol 1998;38:461-499.
451. Zhang L, Zhang YD, Zhao P, Huang S-M. AAPS J 2009;11 (2): 300-306.
452. Chaudhary AK. Bioanalysis going global. Bioanalysis 2009;1 (3): 503-505.
453. Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, Shah VP, Skelly JP, Swann PG, Weiner R. AAPS J 2007;9 (1): Article 4.
454. Fast D, Kelley M, Viswanathan CT, O'Shaughnessy J, Peter King S, Chaudhary A, Weiner R, DeStefano AJ, Tang D. Workshop Report and Follow-Up-AAPS Workshop on Current Topics in GLP Bioanalysis: Assay Reproducibility for Incurred Samples-Implications of Crystal City Recommendations. AAPS J 2009;11 (2): 238-241.
455. United Nations Drug Control Programme. Report of the Consultative Meeting on Quality Assurance and Good Laboratory Practices. Glasgow, 2-6 November 1992.
456. National Institute for Drug Abuse Urine Testing for Drugs of Abuse, Research Monograph 73. Department of Health and Human Services, Rockville, MD, 1986.
457. Miller JC, Miller N, Statistics for Analytical Chemistry. Ellis Horwood, Chichester, 1984.
458. Wennig R. Practical Compendium for Health Professionals: Drugs of Abuse Currently Used in Europe, Publication CEC/V/E/I/Lux 92. Commission of the European Communities, Health and Safety Directorate, Luxembourg, 1992.
459. International Olympic Committee/Reference Materials Committee of the International Organization for, Standardization. Quality control of analytical data produced in chemical laboratories, Publication 271, draft protocol presented to the Fifth International Symposium on the Harmonization of Internal Quality Assurance Schemes for Analytical Laboratories, Washington, DC, July 23, 1993.
460. PONS English Language Dictionary. Collins Cobuild, London, 1987.
461. Garfield FM. Quality Assurance Principles for Analytical Laboratories. Association of Official Analytical Chemists, Arlington, VA, 1991.
462. American Society of Crime Laboratory Directors, Laboratory Accreditation Manual. American Society of Crime Laboratory Directors, Norfolk, VA, 1992.
463. International Organization for Standardization/International Electrotechnical Commission. Guide 25: General Requirements for the Competence of Calibration and Testing Laboratories, Geneva, 1990.
464. Voight WP. Dictionary of Statistics and Methodology: A Non-Technical Guide for the Social Sciences. Sage Publications, Thousand Oaks, CA, 1993.
465. International Organization for Standardization/International Electrotechnical Commission. Guide 2: General Terms and Their Definitions Concerning Standardization and Related Activities, Geneva, 1991.
466. Kendall MG, Buckland WR. A Dictionary of Statistical Terms. Longman Group, London, 1976.
467. Visher C. A Comparison of Urinalysis Technologies for Drug Testing in Criminal Justice. National Institute of Justice and Bureau of Justice Assistance, Washington, DC, 1991.
468. Society of Forensic Toxicologists, Inc./American Academy of Forensic Sciences, Forensic Toxicology Laboratory Guidelines, 1991.
469. Eckschlager K. Errors, Measurement and Results in Chemical Analysis. Van Nostrand Reinhold, London, 1969.
470. International Union of Pure and Applied Chemistry, Spectrochemica Acta, 1978.
471. International Organization for Standardization, International Vocabulary of Basic and General Terms Used in Metrology, Geneva, 1984.
472. National Measurement Accreditation Service, NIS 46, Accreditation for Forensic Analysis and Examination. Teddington, Middlesex, 1992.
473. Recommendations (Alle Rechte Documents, Nils-Eric Saris, cd.). International Federation of Clinical Chemistry, Vol. 1. Walter de Gruyter, New York, 1978-1983.
474. Giacomo P. International Vocabulary of Basic and General Terms in Metrology, Metrology, 1993, 1984, 2nd ed. International Organization for Standardization, Geneva, 1993. ISBN 92-67-01075-1.
475. Horwitz,W. Nomenclature for sampling in analytical chemistry: recommendations (1990) Pure Appl Chem 1990;62:1193-1208.
476. Bennington JL. Saunders Dictionary and Encyclopedia of Laboratory Medicine and Technology. W. B. Saunders Co., New York, 1984.
477. Haeckel, R. Recommendations for definition and determination of carry-over effects. J Autom Chem 1988;10:181-183.
478. Freiser H, Nancollas GH. Compendium of Analytical Nomenclature-Definitive Rules 1987. International Union of Pure and Applied Chemistry-Analytical Chemistry Division. Blackwell Scientific Publications, Oxford, 1987.
479. Development of Definitive Methods for the Notion Ti1 Reference System for the Clinical Laboratory; Approved Guideline, NCCLS Document No. NRSCCL-A, National Committee for Clinical Laboratory Standards, Villanova, PA, 1991.
480. Precision of Test Methods-Determination of Repeatibility and Reproducibility by Interlaboratory Tests, ISO 5725-1981, Proposed Revision Part 4 (1985), International Organization for Standardization, Geneva, Switzerland.
481. Development of Certified Reference Materials for the National Reference System for the Clinical Laboratory; Approved Guideline, NCCLS Document No. NRSCL3-A, National Committee for Clinical Laboratory Standards, Villanova, PA, 1991.
482. Tentative Guidelines for Calibration Materials in Clinical Chemistry, NCCLS Publication 2(17). National Committee for Clinical Laboratory Standards, Villanova, PA, 1982, pp. 499-526.
483. Tentative Guidelines for Control Materials in Clinical Chemistry, NCCLS Publication 2(18). National Committee for Clinical Laboratory Standards, Villanova, PA, 1982, pp. 527-554.
484. Guilbault, GG. and Hjelm, M. Nomenclature for automated and mechanized analysis. Pure Appl Chem, 1989;61:1657-1664.
485. compiled by Gold V, Loening KL, McNaught AD, Schmi P, Compendium of Chemical Terminology, IUPAC Recommendations, Blackwell, 1987.
486. Brewer M, Scott T. Concise Encyclopedia of Biochemistry, Walter de Gruyter, New York, 1983.
487. Bechtler G, Haeckel R, Horder M, Kiiffer H, Porth AJ. Guidelines (1980) for Classification Calculation and Evaluation of Conversion Rates in Clinical Chemistry, IFCC Document 1984, Stage 2, Draft 1. Enzyme Nomenclature Recommendations (1961) of the I.U.B. Enzyme Commission. J Clin Chem Clin Biochem, 1985;23:493-503. J Autoin Chem, 1987;9:105-112.
488. Units of Enzyme Activity, Recommendations, Nomenclature Committee of the International Union of Biochemistry, Eur. J. Biochem., 97319-320, 1979. Correction 104, 1 (1980).
489. Approved Recommendation (1978), Quantity and Units in Clinical Chemistry. IUPAC Section on Clinical Chemistry and IFCC Committee on Standards. Clin Chim Acta, 1979;96:F155-F204.
490. Symbolism and Terminology in Enzyme Kinetics, Recommendations 1981. Nomenclature Committee of the International Union of Biochemistry (NC-IUB). Arch Biochem Biophys 224:732-740, 1983; Biochem J 21356-21371, 1983; Eur J Biochem 128281-128291, 1982.
491. Svehla G. Nomenclature for kinetic methods of analysis. Pure Appl Chem, 1993;652291-652298.
492. Kinetics Analysis of Enzyme Reactions, Tentative Guideline C7T, Vol. 2(9), pp. 271-328, National Committee for Clinical Laboratory Standards, Villanova, PA, 1982.
493. Mills IM, Cvitas T, Kallay N, Homann K, Kuchitsu K,editors. Quantities, Units and Symbolism in Physical Chemistry, International Union of Pure and Applied Chemistry, 2nd edition, Blackwell Scientific Publications, Oxford, 1988; 1993, ISBN 0-632-03583-8.
494. Glossary and Guidelines for Immunodiagnostic Procedures, Reagents and Reference Materials, 2nd ed. Approved Guideline NCCLS Document DII-A2. National Committee for Clinical Laboratory Standards, Villanova, PA, 1992.